Navigation Links
Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease

BETHESDA, Md., March 13, 2007--New evidence suggests that if you could choose your parents, you could reduce your risk of cardiovascular disease. Researchers from the long-standing Framingham Heart Study (FHS), a program of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, report that people whose parents live longer were more likely to avoid developing high blood pressure, high cholesterol, and other risk factors for cardiovascular disease in middle age than their peers whose parents died younger. They also found that the risk factor advantages persisted over time.

According to the researchers, this is the first study to examine cardiovascular risk factors in the offspring of longer-lived individuals using independent and validated measurements of risk. The findings are consistent with other studies that have linked lower cardiovascular risk with parental longevity based on self-reports of family history.

"Characteristics of Framingham Offspring Participants with Long-Lived Parents, appears in the March 12 issue of the Archives of Internal Medicine.

In the study, researchers examined 1,697 offspring age 30 and older (average age 40) whose parents participated in the original FHS and had reached age 85 or died before January 1, 2005. They compared cardiovascular risk factors among the offspring based on whether both parents, one parent, or neither parent lived to 85 years or older. The risk factors included age, sex, education, cigarette smoking, blood pressure, cholesterol, and body mass index (BMI). In addition, they compared the offsprings' Framingham Risk Scores, a summary score based on the combined contribution of traditional cardiovascular risk factors.

In general, the group in which both parents survived to age 85 had significantly fewer participants with high blood pressure or who were current smokers, compared to those in which both
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:5/22/2015)... , May 22, 2015 Today, ... central nervous system stimulant indicated for the treatment ... patients beginning Summer 2015. The ... received approval from the U.S. Food and Drug ... an extended-release formulation of methylphenidate capsule with an ...
(Date:5/22/2015)... May 22, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... interim chief executive officer Howie Rosen will ... financial officer Tim Morris will be presenting ... two presentations are as follows: Jefferies 2015 ...
(Date:5/21/2015)... , May 21, 2015  When Ryan ... the side of his neck, he figured ... a couple weeks off from weight lifting. ... away.                               A series ... was referred to Michel Kliot, MD ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
... Company, Limited (hereafter, Daiichi Sankyo), announced today that the ... (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 ... Welfare in Japan. Edoxaban, which is being ... anticoagulant that specifically, reversibly and directly inhibits the enzyme, ...
... Ontario, April 21, 2011 Valeant Pharmaceuticals International, Inc. ... the following statement to shareholders of Cephalon, Inc. (NASDAQ: ... today, the Cephalon Board of Directors stated that it ... Company,s alternatives and options – and is focused on ...
Cached Medicine Technology:Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 2Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 3Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery 4Valeant Pharmaceuticals Responds to Cephalon Board's Letter 2Valeant Pharmaceuticals Responds to Cephalon Board's Letter 3Valeant Pharmaceuticals Responds to Cephalon Board's Letter 4
(Date:5/22/2015)... 2015 A Phase 3 French ... Society of Clinical Oncology (ASCO)’s annual meeting at ... for those patients who received bevacizumab in addition ... Bevacizumab (Avastin® Genentech, Inc.) is an antibody that ... already routinely used to treat many other cancers, ...
(Date:5/22/2015)... 2015 In an effort to support ... is offering to donate $5 dollars for every maintenance ... or water softening system. Customers have their needs serviced, ... gets business; and the Special Olympics receives money. Hence ... helps over 4.4 million athletes, and boasts a myriad ...
(Date:5/22/2015)... 2015 A new program for the ... the field of Physical Therapy. , James Earl ... mystery out of physical therapy and discusses how the ... for a variety of ailments and injuries. Physical ... exercise plan that enhances daily activities such as house ...
(Date:5/22/2015)... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... religious leaders to make changes in order to achieve peace ... discusses the history of war, how it started, why it ... mankind was created to lead peaceful, joyful lives, very much ... “Yahweh created mankind, according to His Plan, which is still ...
(Date:5/21/2015)... York, New York (PRWEB) May 21, 2015 ... distributor of patented products, launches the Troll Motor Guide, ... convenient way of boating. , "The recreational boating industry ... Scott J. Cooper, CEO and Creative Director of ... water in record numbers and predicts continued steady growth ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Parker and Sons is Proud to Support the Special Olympics with Their Everybody Wins Program 2Health News:Yisrayl Hawkins Calls on All Religions to Wake Up and Make Drastic Changes to End Suffering in New Letter 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 2Health News:Great Ways To Celebrate On Memorial Day Weekend- Starting With World Patent Marketing's New Boat Patent 3
... of Vermont will elevate the state to being the second ... health-care insurance// , which will cover nearly 96 percent of ... definitely relief for the 46 million Americans who are not ... and costs of insurance premium showing an upward trend, this ...
... getting dirtier despite promises, claimed patients in a survey despite ... ,The annual NHS patients survey has found high levels of ... questions were asked of the 80,000 people who took part ... ward ha been ‘very clean’ as compared to 56% in ...
... Scotland's health minister Andy Kerr said that the NHS staff ... latest statistics on NHS waiting times// as the "best ever". ... had reduced from 12 to 6 months. ,Reports ... number of outpatients and inpatient day cases with an 18-week ...
... cases of diarrhoea in Ranchi, the Jharkhand Health department ... with the disease. // ,'We have equipped ... free-of-cost treatment to patients,' Health and Family Welfare's joint ... patients to avail free treatment at the hospital instead ...
... world , including India, must face the challenges of ... their citizens get access to effective healthcare // , ... medical expenses, a new World Bank report said. ... to cope with sharply rising costs even while countries ...
... by the Indian Medical Association, the junior doctors of ... colleges today struck work launching a one-day strike. ... and government dental hospitals were 'totally shut down', emergency ... Assoication, BMC told PTI., ,'We will watch the ...
Cached Medicine News:Health News:Quality Of NHS Hospitals Getting Dirtier Despite Promises 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 3
An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
An enzyme linked immunoassay (ELISA) for the detection and semiquantitation of IgG, IgA or IgM anticardiolipin antibodies, as an aid in assessing the risk of thrombosis in individuals with Systemic L...
The ImagingPlanet 70 mm surgical microscope video adapter: superior optical quality and precise engineering make this 70 mm focal length adapter an excellent decision for use with your Zeiss surgical...
The ImagingPlanet 55 mm surgical microscope video adapter: superior optical quality and precise engineering make this 55mm focal length adapter an excellent decision for use with your Leica surgical ...
Medicine Products: